scholarly journals Metabolic Syndrome in Childhood Cancer Survivors: Does Delta BMI Predict Risk in Lower-middle-income Countries?

Author(s):  
Arushi Agarwal ◽  
Gauri Kapoor ◽  
Sandeep Jain ◽  
Payal Malhotra ◽  
Anurag Sharma

Abstract Purpose Metabolic syndrome (MetSyn) is an important late effect of childhood cancer. The combination of rising obesity and high prevalence of under-nutrition at diagnosis, make this a unique population to study in LMIC (lower middle-income countries). Methods Children <18 years of age at cancer diagnosis, in a single-centre in a LMIC, who were disease free and had completed treatment at least 2 years prior to study were included. MetSyn was defined using International Federation for Diabetes criteria for Asian Indians. Logistic regression analyses were carried out to evaluate the influence of various risk factors, including delta BMI (increase in body mass index from diagnosis to evaluation), on MetSyn.Results A high prevalence of MetSyn (12.2%), central obesity (33%), and dyslipidemia (61.8%) was found in a cohort of 500 Asian Indian childhood cancer survivors (CCS) at a median follow-up age of 17 years. Multivariable analysis revealed older age at diagnosis >10 years, OR 2.9(1.6-5), longer survival duration >10 years, OR 2.2(1.3-3.8), high BMI at diagnosis OR 3.2(1.5-6.9) and large delta BMI >50, OR 3.15(1.7-5.9) to be independent predictors of MetSyn. Patients who were under-weight or normal at diagnosis with large Delta BMI > 50 had very high odds (OR, 12.5,1.7-92) of developing MetSyn compared to those with lower Delta BMI. Conclusions and implications for cancer survivors: A high prevalence of MetSyn was observed in CCS with early age at onset. Timely screening and early intervention are proven to be beneficial and delta BMI could be a useful screening tool for LMIC.

2019 ◽  
Vol 91 (2) ◽  
pp. 118-127 ◽  
Author(s):  
Danielle Novetsky Friedman ◽  
Emily S. Tonorezos ◽  
Paul Cohen

Endocrine complications, including diabetes and metabolic syndrome, are highly prevalent in childhood cancer survivors. These metabolic derangements may contribute to survivors’ risk of excess cardiovascular morbidity and premature mortality. This review summarizes existing knowledge on risk of diabetes and metabolic syndrome among childhood cancer survivors, focusing specifically on known risk factors, potential mechanisms, and screening recommendations. Early diagnosis via standardized risk-based screening can improve long-term outcomes in this population. Additional work is needed to elucidate the mechanisms underlying these metabolic complications and to inform the design of risk-reducing interventions and optimize long-term cardiometabolic health among survivors of childhood cancer.


2013 ◽  
Vol 55 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Chiaki Kojima ◽  
Masaru Kubota ◽  
Ayako Nagai ◽  
Souichi Adachi ◽  
Ken-Ichiro Watanabe ◽  
...  

2013 ◽  
Vol 49 (3) ◽  
pp. 668-675 ◽  
Author(s):  
Marjolein van Waas ◽  
Sebastian J.C.M.M. Neggers ◽  
André G. Uitterlinden ◽  
Karin Blijdorp ◽  
Ivana M.M. van der Geest ◽  
...  

2011 ◽  
Vol 54 (6) ◽  
pp. 253 ◽  
Author(s):  
Young Bae Sohn ◽  
Su Jin Kim ◽  
Sung Won Park ◽  
Se-Hwa Kim ◽  
Sung-Yoon Cho ◽  
...  

2020 ◽  
Author(s):  
Vincent Pluimakers ◽  
Marta Fiocco ◽  
Jenneke van Atteveld ◽  
Monique Hobbelink ◽  
Dorine Bresters ◽  
...  

BACKGROUND Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia and hypertension. These risk factors cluster together as metabolic syndrome (MetS) and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis and preventive strategies is of importance to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no studies in national cohorts on prevalence and determinants of MetS in childhood cancer survivors including biomarkers and genetic predisposition are available. OBJECTIVE The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of MetS and its separate components, and 2) the potential value of additional biomarkers, in the national cohort of adult long-term survivors of childhood cancer. METHODS This is a cross-sectional study, based on recruitment of all survivors treated in the Netherlands between 1963 and 2002. MetS will be classified according to the definitions of the National Cholesterol Education Program (NCEP-ATP III) as well as the Joint Interim Statement (JIS), and compared to reference data. Dual-energy X-ray absorptiometry (DXA) scans were performed to assess body composition in more detail. The effect of patient characteristics, previous treatment, and genetic variation on the risk of MetS will be assessed. The diagnostic and predictive value of novel biomarkers will be tested. RESULTS Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors has participated, in seven pediatric oncology hospitals. From July 2020, biomarker testing, SNP analysis and data analysis will be performed. CONCLUSIONS The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of MetS, and the diagnostic value of biomarkers, in childhood cancer survivors. The results of this study will be used to optimize surveillance guidelines for MetS in survivors, based on enhanced risk stratification and screening strategies. This will improve diagnosis of MetS, and prevent complications. CLINICALTRIAL Registered at toetsingonline.nl, NL32117.018.10


Sign in / Sign up

Export Citation Format

Share Document